On Estimating Medical Cost and Incremental Cost‐Effectiveness Ratios with Censored Data
Abstract
Summary. Medical cost estimation is very important to health care organizations and health policy makers. We consider cost‐effectiveness analysis for competing treatments in a staggered‐entry, survival‐analysis‐based clinical trial. We propose a method for estimating mean medical cost over patients in such settings. The proposed estimator is shown to be consistent and asymptotically normal, and its asymptotic variance can be obtained. In addition, we propose a method for estimating the incremental cost‐effectiveness ratio and for obtaining a confidence interval for it. Simulation experiments are conducted to evaluate our proposed methods. Finally, we apply our methods to a clinical trial comparing the cost effectiveness of implanted cardiac defibrillators with conventional therapy for individuals at high risk for ventricular arrhythmias.
Citing Literature
Number of times cited according to CrossRef: 55
- Kevin T. Stroupe, Bridget Smith, Frances M. Weaver, Beverly Gonzalez, Zhiping Huo, Lishan Cao, Dolores Ippolito, Kenneth A. Follett, Healthcare Utilization and Costs for Patients With Parkinson's Disease After Deep Brain Stimulation, Movement Disorders Clinical Practice, 10.1002/mdc3.12765, 6, 5, (369-378), (2019).
- Lars Børty, Rasmus Brøndum, Martin Bøgsted, ccostr: An R package for estimating mean costs with censored data, Journal of Open Source Software, 10.21105/joss.01593, 4, 41, (1593), (2019).
- Lu Deng, Wendy Lou, Nicholas Mitsakakis, Modeling right-censored medical cost data in regression and the effects of covariates, Statistical Methods & Applications, 10.1007/s10260-018-0428-0, 28, 1, (143-155), (2018).
- Charissa R. Kim, Bumyang Kim, Matthew S. Ning, Jay P. Reddy, Zhongxing Liao, Chad Tang, James W. Welsh, Frank E. Mott, Ya-Chen Tina Shih, Daniel R. Gomez, Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non–Small-Cell Lung Cancer After Definitive Radiation Therapy, Clinical Lung Cancer, 10.1016/j.cllc.2018.03.012, 19, 4, (e517-e528), (2018).
- Hubert Y. Pan, Jing Jiang, Karen E. Hoffman, Chad Tang, Seungtaek L. Choi, Quynh-Nhu Nguyen, Steven J. Frank, Mitchell S. Anscher, Ya-Chen Tina Shih, Benjamin D. Smith, Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer, Journal of Clinical Oncology, 10.1200/JCO.2017.75.5371, 36, 18, (1823-1830), (2018).
- Shuai Chen, Jennifer Rolfes, Hongwei Zhao, Estimation of Mean Health Care Costs and Incremental Cost-effectiveness Ratios with Possibly Censored Data, The Stata Journal: Promoting communications on statistics and Stata, 10.1177/1536867X1501500305, 15, 3, (698-711), (2018).
- Elizabeth A Handorf, Daniel F Heitjan, Justin E Bekelman, Nandita Mitra, Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders, Statistical Methods in Medical Research, 10.1177/0962280218759137, (096228021875913), (2018).
- Shuai Chen, Wenbin Lu, Hongwei Zhao, An improved survival estimator for censored medical costs with a kernel approach, Communications in Statistics - Theory and Methods, 10.1080/03610926.2017.1400059, 47, 23, (5702-5716), (2017).
- Chenghui Li, George E. MacKinnon, Chapter 5: Overview of Statistical Analysis in Biomedical Research, Understanding Health Outcomes and Pharmacoeconomics, 10.21019/9781582122823, (2017).
- Jenny Jeyarajah, Gengsheng Qin, Empirical likelihood‐based confidence intervals for mean medical cost with censored data, Statistics in Medicine, 10.1002/sim.7402, 36, 25, (4061-4070), (2017).
- Yifei Sun, Mei-Cheng Wang, Evaluating Utility Measurement From Recurrent Marker Processes in the Presence of Competing Terminal Events, Journal of the American Statistical Association, 10.1080/01621459.2016.1166113, 112, 518, (745-756), (2017).
- Mei-Cheng Wang, Yifei Sun, Nonparametric estimation of medical cost quantiles in the presence of competing terminal events, Biostatistics & Epidemiology, 10.1080/24709360.2017.1342185, 1, 1, (78-91), (2017).
- Jiaqi Li, Anil Vachani, Andrew Epstein, Nandita Mitra, A doubly robust approach for cost–effectiveness estimation from observational data, Statistical Methods in Medical Research, 10.1177/0962280217693262, (096228021769326), (2017).
- Liang Li, Chih-Hsien Wu, Jing Ning, Xuelin Huang, Ya-Chen Tina Shih, Yu Shen, Semiparametric Estimation of Longitudinal Medical Cost Trajectory, Journal of the American Statistical Association, 10.1080/01621459.2017.1361329, (0-0), (2017).
- Dianliang Deng, Estimating the cumulative mean function for history process with time‐dependent covariates and censoring mechanism, Statistics in Medicine, 10.1002/sim.6998, 35, 25, (4624-4636), (2016).
- N. Mounier, C. Ferme, H. Flechtner, M. M. Henry-Amar, E. Lepage, Model-Based Methodology for Analyzing Incomplete Quality-of-Life Data and Integrating Them into the Q-Twist Framework, Medical Decision Making, 10.1177/0272989X02239650, 23, 1, (54-66), (2016).
- A R Willan, D Y Lin, R J Cook, E B Chen, Using inverse-weighting in cost-effectiveness analysis with censored data, Statistical Methods in Medical Research, 10.1191/0962280202sm308ra, 11, 6, (539-551), (2016).
- A O’Hagan, J W Stevens, Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies, Statistical Methods in Medical Research, 10.1191/0962280202sm305ra, 11, 6, (469-490), (2016).
- Heejung Bang, Hongwei Zhao, Median-based incremental cost-effectiveness ratios with censored data, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2015.1052482, 26, 3, (552-564), (2015).
- Laura M. Yee, Kwun Chuen Gary Chan, Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios, Statistics in Medicine, 10.1002/sim.6594, 34, 30, (4057-4069), (2015).
- Shangyu Xie, Alan T.K. Wan, Yong Zhou, Quantile regression methods with varying-coefficient models for censored data, Computational Statistics & Data Analysis, 10.1016/j.csda.2015.02.011, 88, (154-172), (2015).
- Matthew C. Cheung, Annette E. Hay, Michael Crump, Kevin R. Imrie, Yuyao Song, Shazia Hassan, Nancy Risebrough, Jonathan Sussman, Stephen Couban, David MacDonald, Vishal Kukreti, C. Tom Kouroukis, Tara Baetz, David Szwajcer, Pierre Desjardins, Lois Shepherd, Ralph M. Meyer, Al Le, Bingshu E. Chen, Nicole Mittmann, Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12, JNCI: Journal of the National Cancer Institute, 10.1093/jnci/djv106, 107, 7, (2015).
- Heejung Bang, Hongwei Zhao, Cost-Effectiveness Analysis: A Proposal of New Reporting Standards in Statistical Analysis, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2013.860157, 24, 2, (443-460), (2014).
- Andrew R Willan, Statistical analysis of cost–effectiveness data from randomized clinical trials, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1586/14737167.6.3.337, 6, 3, (337-346), (2014).
- Shuai Chen, Hongwei Zhao, Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data, Journal of Statistical Theory and Practice, 10.1080/15598608.2013.771556, 7, 2, (304-323), (2013).
- S. Chen, H. Zhao, Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs, Biostatistics, 10.1093/biostatistics/kxt002, 14, 3, (422-432), (2013).
- KATIA NOYES, PETER VEAZIE, WILLIAM JACKSON HALL, HONGWEI ZHAO, APRIL BUTTACCIO, KELLY THEVENET‐MORRISON, ARTHUR J. MOSS, Cost‐Effectiveness of Cardiac Resynchronization Therapy in the MADIT‐CRT Trial, Journal of Cardiovascular Electrophysiology, 10.1111/j.1540-8167.2012.02413.x, 24, 1, (66-74), (2012).
- Hongwei Zhao, Chen Zuo, Shuai Chen, Heejung Bang, Nonparametric Inference for Median Costs with Censored Data, Biometrics, 10.1111/j.1541-0420.2012.01755.x, 68, 3, (717-725), (2012).
- Heejung Bang, Hongwei Zhao, Median-Based Incremental Cost-Effectiveness Ratio (ICER), Journal of Statistical Theory and Practice, 10.1080/15598608.2012.695571, 6, 3, (428-442), (2012).
- Robert I. Griffiths, Michelle L. Gleeson, Mark D. Danese, Anthony O'Hagan, Inverse Probability Weighted Least Squares Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEER-Medicare, Value in Health, 10.1016/j.jval.2012.03.1388, 15, 5, (656-663), (2012).
- Heejung Bang, Hongwei Zhao, Average Cost-Effectiveness Ratio with Censored Data, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2010.544437, 22, 2, (401-415), (2012).
- H. Zhao, Y. Cheng, H. Bang, Some insight on censored cost estimators, Statistics in Medicine, 10.1002/sim.4295, 30, 19, (2381-2388), (2011).
- Hong-Bin Fang, Jiantian Wang, Dianliang Deng, Man-Lai Tang, Estimating the mean of a mark variable under right censoring on the basis of a state function, Computational Statistics & Data Analysis, 10.1016/j.csda.2010.10.028, 55, 4, (1726-1735), (2011).
- Serena P. Koenig, Heejung Bang, Patrice Severe, Marc Antoine Jean Juste, Alex Ambroise, Alison Edwards, Jessica Hippolyte, Daniel W. Fitzgerald, Jolion McGreevy, Cynthia Riviere, Serge Marcelin, Rode Secours, Warren D. Johnson, Jean W. Pape, Bruce R. Schackman, Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti, PLoS Medicine, 10.1371/journal.pmed.1001095, 8, 9, (e1001095), (2011).
- Lois G. Kim, Simon G. Thompson, Estimation of life‐years gained and cost effectiveness based on cause‐specific mortality, Health Economics, 10.1002/hec.1648, 20, 7, (842-852), (2010).
- Albert Vexler, Jihnhee Yu, Lili Tian, Shuling Liu, Two‐sample nonparametric likelihood inference based on incomplete data with an application to a pneumonia study, Biometrical Journal, 10.1002/bimj.200900131, 52, 3, (348-361), (2010).
- Jihnhee Yu, Albert Vexler, Lili Tian, Analyzing Incomplete Data Subject to a Threshold using Empirical Likelihood Methods: An Application to a Pneumonia Risk Study in an ICU Setting, Biometrics, 10.1111/j.1541-0420.2009.01228.x, 66, 1, (123-130), (2009).
- Yijian Huang, Cost Analysis With Censored Data, Medical Care, 10.1097/MLR.0b013e31819bc08a, 47, Supplement, (S115-S119), (2009).
- Paul S. Chan, Gabriel Soto, Philip G. Jones, Brahmajee K. Nallamothu, Zefeng Zhang, William S. Weintraub, John A. Spertus, Patient Health Status and Costs in Heart Failure, Circulation, 10.1161/CIRCULATIONAHA.108.820472, 119, 3, (398-407), (2009).
- Hongkun Wang, Hongwei Zhao, A Study on Confidence Intervals for Incremental Cost‐Effectiveness Ratios, Biometrical Journal, 10.1002/bimj.200810439, 50, 4, (505-514), (2008).
- Eva Pagano, Michele Petrinco, Alessandro Desideri, Riccardo Bigi, Franco Merletti, Dario Gregori, Survival models for cost data: The forgotten additive approach, Statistics in Medicine, 10.1002/sim.3215, 27, 18, (3585-3597), (2008).
- Lu Tian, Jie Huang, A two‐part model for censored medical cost data, Statistics in Medicine, 10.1002/sim.2847, 26, 23, (4273-4292), (2007).
- Hongwei Zhao, Heejung Bang, Hongkun Wang, Phillip E. Pfeifer, On the equivalence of some medical cost estimators with censored data, Statistics in Medicine, 10.1002/sim.2882, 26, 24, (4520-4530), (2007).
- Christel Castelli, Christophe Combescure, Yohann Foucher, Jean‐Pierre Daures, Cost‐effectiveness analysis in colorectal cancer using a semi‐Markov model, Statistics in Medicine, 10.1002/sim.3112, 26, 30, (5557-5571), (2007).
- Raymond Ng, Baktiar Hasan, Nicole Mittmann, Marie Florescu, Frances A. Shepherd, Keyue Ding, Charles Andrew Butts, Yvon Cormier, Gail Darling, Glenwood D. Goss, Richard Inculet, Lesley Seymour, Timothy L. Winton, William K. Evans, Natasha B. Leighl, Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, 10.1200/JCO.2006.09.4342, 25, 16, (2256-2261), (2007).
- Heejung Bang, Clarence E. Davis, On estimating treatment effects under non‐compliance in randomized clinical trials: are intent‐to‐treat or instrumental variables analyses perfect solutions?, Statistics in Medicine, 10.1002/sim.2663, 26, 5, (954-964), (2006).
- Jack Zwanziger, W. Jackson Hall, Andrew W. Dick, Hongwei Zhao, Alvin I. Mushlin, Rebecca Marron Hahn, Hongkun Wang, Mark L. Andrews, Cathleen Mooney, Hongyue Wang, Arthur J. Moss, The Cost Effectiveness of Implantable Cardioverter-Defibrillators, Journal of the American College of Cardiology, 10.1016/j.jacc.2006.03.032, 47, 11, (2310-2318), (2006).
- Hongkun Wang, Hongwei Zhao, Estimating Incremental Cost‐Effectiveness Ratios and Their Confidence Intervals with Differentially Censored Data, Biometrics, 10.1111/j.1541-0420.2005.00502.x, 62, 2, (570-575), (2006).
- Heejung Bang, Medical cost analysis: Application to colorectal cancer data from the SEER Medicare database, Contemporary Clinical Trials, 10.1016/j.cct.2005.05.004, 26, 5, (586-597), (2005).
- Phillip E. Pfeifer, Heejung Bang, Non‐parametric estimation of mean customer lifetime value, Journal of Interactive Marketing, 10.1002/dir.20049, 19, 4, (48-66), (2005).
- Elamin H. Elbasha, Risk aversion and uncertainty in cost‐effectiveness analysis: the expected‐utility, moment‐generating function approach, Health Economics, 10.1002/hec.915, 14, 5, (457-470), (2004).
- Andrew R. Willan, D. Y. Lin, Andrea Manca, Regression methods for cost‐effectiveness analysis with censored data, Statistics in Medicine, 10.1002/sim.1794, 24, 1, (131-145), (2004).
- Daniel F. Heitjan, Clara Yuri Kim, Huiling Li, Bayesian estimation of cost‐effectiveness from censored data, Statistics in Medicine, 10.1002/sim.1740, 23, 8, (1297-1309), (2004).
- Anthony O’Hagan, John W. Stevens, On estimators of medical costs with censored data, Journal of Health Economics, 10.1016/j.jhealeco.2003.06.006, 23, 3, (615-625), (2004).
- Andrew R Willan, Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp Trial, European Journal of Gastroenterology & Hepatology, 10.1097/00042737-200406000-00006, 16, 6, (543-549), (2004).




